Hospital laboratory reporting may be a barrier to detection of ‘microsize-myocardial infarction in the US: an observational study

详细信息    查看全文

• 作者：Monika M Safford (17)
  Gaurav Parmar (17)
  Codrin S Barasch (17)
  Jewell H Halanych (17)
  Stephen P Glasser (17)
  David C Goff (18)
  Ronald J Prineas (19)
  Todd M Brown (20)
  
• 关键词：Acute coronary syndrome ; Troponin ; Quality control
• 刊名：BMC Health Services Research
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：196KB
• 参考文献：1. Thygesen K, Alpert JS, White HD: Universal definition of myocardial infarction. / J Am Coll Cardiol 2007,50(22):2173-195. CrossRef
  2. Thygesen K, Alpert JS, White HD: Universal definition of myocardial infarction. / Eur Heart J 2007,28(20):2525-538. CrossRef
  3. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B: Universal definition of myocardial infarction. / Circulation 2007,116(22):2634-653. CrossRef
  4. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG: Case definitions for acute coronary heart disease in epidemiology and clinical research studies: A statement from the AHA Council on Epidemiology and Prevention, AHA Statistics Committee, World Heart Federation Council on Epidemiology and Prevention, European Society of Cardiology Working Group on Epidemiology and Prevention, Centers for Disease Control and Prevention, and the National Heart Lung and Blood Institute. / Circulation 2003,108(20):2543-549. CrossRef
  5. Hochholzer W, Buettner HJ, Trenk D, Laule K, Christ M, Neumann FJ, Mueller C: New definition of myocardial infarction: impact on long-term mortality. / Am J Med 2008,121(5):399-05. CrossRef
  6. Mueller C, Neumann FJ, Perruchoud AP, Zeller T, Buettner HJ: Prognostic value of quantitative troponin T measurements in unstable angina/non-ST-segment elevation acute myocardial infarction treated early and predominantly with percutaneous coronary intervention. / Am J Med 2004,117(12):897-02. CrossRef
  7. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O’Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr: Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. / N Engl J Med 1996,335(18):1333-341. CrossRef
  8. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. / N Engl J Med 1996,335(18):1342-349. CrossRef
  9. Pham HH, Schrag D, Hargraves JL, Bach PB: Delivery of preventive services to older adults by primary care physicians. / JAMA 2005,294(4):473-81. CrossRef
  10. Alpert JS, Malasky BR, Thygesen K: Redefining myocardial infarction for the 21st century. / Trans Am Clin Climatol Assoc 2004, 115:79-6.
  11. Alpert JS, Thygesen K: A call for universal definitions in cardiovascular disease. / Circulation 2006,114(8):757-58. CrossRef
  12. Alpert JS, Thygesen K: A new global definition of myocardial infarction for the 21st century. / Pol Arch Med Wewn 2007,117(11-2):485-86.
  13. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. / J Am Coll Cardiol 2000,36(3):959-69. CrossRef
  14. Alpert JS, Thygesen K, Jaffe A, White HD: The universal definition of myocardial infarction: a consensus document: ischaemic heart disease. / Heart 2008,94(10):1335-341. CrossRef
  15. / International federation of Clinical Chemistry and Laboratory Medicine. Analytic characteristics of commerical cardiac troponin I and T assays as stated by manufacturer (version October 2008). 2013. http://www.ifcc.org/media/102202/IFCC_Troponin_Table_vDec_2010_FINAL_ug_L_28Jan11.pdf, accessed May 6
  16. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS: Population trends in the incidence and outcomes of acute myocardial infarction. / N Engl J Med 2010,362(23):2155-165. CrossRef
  17. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ: Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. / Am J Med 2011,124(1):40-7. CrossRef
  18. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, Moy CS, Howard G: The reasons for geographic and racial differences in stroke study: objectives and design. / Neuroepidemiology 2005,25(3):135-43. CrossRef
  19. / International Federation of Clinical Chemistry and Laboratory Medicine. C-SMCD Cardiac Troponin Assays. 2013. http://www.ifcc.org/media/102199/IFCC_Troponin_Table_vDec_2010_FINAL_ng_L_28Jan11.pdf, accessed May 6,
  20. Morrow DA: Evidence-based decision limits for cardiac troponin: low-level elevation and prognosis. / Am Heart J 2004,148(5):739-42. CrossRef
  21. Urban P, Radovanovic D, Erne P, Stauffer JC, Pedrazzini G, Windecker S, Bertel O: Impact of changing definitions for myocardial infarction: a report from the AMIS registry. / Am J Med 2008,121(12):1065-071. CrossRef
  22. Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS, Paterson E, MacLeod M, Graham C, Walker S: Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. / JAMA 2011,305(12):1210-216. CrossRef
  23. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B: Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality. / Circulation 2007,116(17):1907-914. CrossRef
  24. Zethelius B, Johnston N, Venge P: Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. / Circulation 2006,113(8):1071-078. CrossRef
  25. Waxman DA, Hecht S, Schappert J, Husk G: A model for troponin I as a quantitative predictor of in-hospital mortality. / J Am Coll Cardiol 2006,48(9):1755-762. CrossRef
  26. Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM: Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. / Am Heart J 2002,144(6):957-80. CrossRef
  27. / Accountability Measaures. A New Concept to Promote Quality Improvement. 2013. http://www.jointcommission.org/accountability_measures.aspx, accessed May 6,
  28. / Premier Hospital Quality Incentive Demonstration. 2013. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/index.html?redirect=/hospitalqualityinits, accessed May 6,
  29. / CDC Wonder Compressed Mortality File. [http://wonder.cdc.gov/mortsql.html]
  30. Hugtenburg JG, Blom AT, Kisoensingh SU: Initial phase of chronic medication use; patients-reasons for discontinuation. / Br J Clin Pharmacol 2006,61(3):352-54. CrossRef
  31. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. / Circulation 2006,113(24):2803-809. CrossRef
  32. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS: Impact of medication therapy discontinuation on mortality after myocardial infarction. / Arch Intern Med 2006,166(17):1842-847. CrossRef
  33. Halim SA, Mulgund J, Chen AY, Matthew TR, Peterson ED, Gibler WB, Ohman EM, Newby LK: Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation. / Circ Cardiovasc Qual Outcomes 2009,2(3):199-06. CrossRef
  34. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6963/13/162/prepub
  
• 作者单位：Monika M Safford (17)
  Gaurav Parmar (17)
  Codrin S Barasch (17)
  Jewell H Halanych (17)
  Stephen P Glasser (17)
  David C Goff (18)
  Ronald J Prineas (19)
  Todd M Brown (20)
  
  17. Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Medical Towers 621, 1717 11th Avenue South, Birmingham, AL, 35294-4410, USA
  18. Colorado School of Public Health, Building 500, 3rd Floor, Suite 300, Anschutz Medical Campus, Aurora, CO, 80045, USA
  19. Department of Epidemiology & Prevention, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1063, USA
  20. Division of Cardiovascular Disease, University of Alabama at Birmingham School of Medicine, 701 19th Street South, Birmingham, AL, 35294-0007, USA
  

文摘

Background International guidelines recommend that the decision threshold for troponin should be the 99th percentile of a normal population, or, if the laboratory assay is not sufficiently precise at this low level, the level at which the assay achieves a 10% or better coefficient of variation (CV). Our objectives were to examine US hospital laboratory troponin reports to determine whether either the 99th percentile or the 10% CV level were clearly indicated, and whether nonconcordance with these guidelines was a potential barrier to detecting clinically important microscopic or ‘microsize-myocardial infarctions (MIs). To confirm past reports of the clinical importance of microsize MIs, we also contrasted in-hospital, 28-day and 1-year mortality among those with microsize and nonmicrosize MI. Methods In the REasons for Geographic And Racial Differences in Stroke national prospective cohort study (n=30,239), 1029 participants were hospitalized for acute coronary syndrome (ACS) between 2003-009. For each case, we recorded all thresholds of abnormal troponin on the laboratory report and whether the 99th percentile or 10% CV value were clearly identified. All cases were expert adjudicated for presence of MI. Peak troponin values were used to classify MIs as microsize MI (< five times the lowest listed upper limit of normal) and nonmicrosize MI. Results Participants were hospitalized at 649 acute care US hospitals, only 2% of whose lab reports clearly identified the 99th percentile or the 10% CV level; 52% of reports indicated an indeterminate range, a practice that is no longer recommended. There were 183 microsize MIs and 353 nonmicrosize MIs. In-hospital mortality tended to be lower in the microsize than in the nonmicrosize MI group (1.1 vs. 3.6%, p--.09), but 28-day and 1-year mortality were similar (2.5% vs. 2.7% [p--.93] and 5.2% vs. 4.3% [p--.64], respectively). Conclusions Current practices in many US hospitals created barriers to the clinical recognition of microsize MI, which was common and clinically important in our study. Improved hospital troponin reporting is warranted.